450 related articles for article (PubMed ID: 9642098)
1. An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene.
Persons DA; Mehaffey MG; Kaleko M; Nienhuis AW; Vanin EF
Blood Cells Mol Dis; 1998 Jun; 24(2):167-82. PubMed ID: 9642098
[TBL] [Abstract][Full Text] [Related]
2. A convenient method for positive selection of retroviral producing cells generating vectors devoid of selectable markers.
Xu L; Tsuji K; Mostowski H; Otsu M; Candotti F; Rosenberg AS
J Virol Methods; 2004 Jun; 118(1):61-7. PubMed ID: 15158069
[TBL] [Abstract][Full Text] [Related]
3. Reliable generation of stable high titer producer cell lines for gene therapy.
Rattmann I; Kleff V; Feldmann A; Ludwig C; Sorg UR; Opalka B; Moritz T; Flasshove M
Intervirology; 2007; 50(3):197-203. PubMed ID: 17283445
[TBL] [Abstract][Full Text] [Related]
4. Large-scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols.
Farson D; McGuinness R; Dull T; Limoli K; Lazar R; Jalali S; Reddy S; Pennathur-Das R; Broad D; Finer M
J Gene Med; 1999; 1(3):195-209. PubMed ID: 10738568
[TBL] [Abstract][Full Text] [Related]
5. A comparative evaluation of gene transfer into blood cells using the same retroviral backbone for independent expression of the EGFP and deltaLNGFR marker genes.
Giaretta I; Madeo D; Bonaguro R; Cappellari A; Rodeghiero F; Giorgio P
Haematologica; 2000 Jul; 85(7):680-9. PubMed ID: 10897118
[TBL] [Abstract][Full Text] [Related]
6. A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors.
Schucht R; Coroadinha AS; Zanta-Boussif MA; Verhoeyen E; Carrondo MJ; Hauser H; Wirth D
Mol Ther; 2006 Aug; 14(2):285-92. PubMed ID: 16697259
[TBL] [Abstract][Full Text] [Related]
7. Generation of a conditionally neo(r)-containing retroviral producer cell line: effects of neo(r) on retroviral titer and transgene expression.
Wildner O; Candotti F; Krecko EG; Xanthopoulos KG; Ramsey WJ; Blaese RM
Gene Ther; 1998 May; 5(5):684-91. PubMed ID: 9797874
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the relative level of gene expression from different retroviral vectors used for gene therapy.
Byun J; Kim SH; Kim JM; Yu SS; Robbins PD; Yim J; Kim S
Gene Ther; 1996 Sep; 3(9):780-8. PubMed ID: 8875226
[TBL] [Abstract][Full Text] [Related]
9. A rapid screening procedure for the identification of high-titer retrovirus packaging clones.
Murdoch B; Pereira DS; Wu X; Dick JE; Ellis J
Gene Ther; 1997 Jul; 4(7):744-9. PubMed ID: 9282176
[TBL] [Abstract][Full Text] [Related]
10. Generation of high-titer retroviral vectors following receptor-mediated, adenovirus-augmented transfection.
von Rüden T; Stingl L; Cotten M; Wagner E; Zatloukal K
Biotechniques; 1995 Mar; 18(3):484-9. PubMed ID: 7779400
[TBL] [Abstract][Full Text] [Related]
11. Sorting vector producer cells for high transgene expression increases retroviral titer.
Beaudoin EL; Bais AJ; Junghans RP
J Virol Methods; 2008 Mar; 148(1-2):253-9. PubMed ID: 18249448
[TBL] [Abstract][Full Text] [Related]
12. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
[TBL] [Abstract][Full Text] [Related]
13. Construction of a high efficiency retroviral vector for gene therapy of Hunter's syndrome.
Hong Y; Yu SS; Kim JM; Lee K; Na YS; Whitley CB; Sugimoto Y; Kim S
J Gene Med; 2003 Jan; 5(1):18-29. PubMed ID: 12516048
[TBL] [Abstract][Full Text] [Related]
14. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors.
Cockrell AS; Ma H; Fu K; McCown TJ; Kafri T
Mol Ther; 2006 Aug; 14(2):276-84. PubMed ID: 16516556
[TBL] [Abstract][Full Text] [Related]
15. Use of bicistronic retroviral vectors encoding the LacZ gene together with a gene of interest: a method to select producer cells and follow transduced target cells.
Staal FJ; Bakker AQ; Verkuijlen M; van Oort E; Spits H
Cancer Gene Ther; 1996; 3(5):345-51. PubMed ID: 8894254
[TBL] [Abstract][Full Text] [Related]
16. The use of recombinase mediated cassette exchange in retroviral vector producer cell lines: predictability and efficiency by transgene exchange.
Coroadinha AS; Schucht R; Gama-Norton L; Wirth D; Hauser H; Carrondo MJ
J Biotechnol; 2006 Jul; 124(2):457-68. PubMed ID: 16529836
[TBL] [Abstract][Full Text] [Related]
17. Construction of new retroviral producer cells from adenoviral and retroviral vectors.
Lin X
Gene Ther; 1998 Sep; 5(9):1251-8. PubMed ID: 9930327
[TBL] [Abstract][Full Text] [Related]
18. Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: improved safety and high titer.
Sheridan PL; Bodner M; Lynn A; Phuong TK; DePolo NJ; de la Vega DJ; O'Dea J; Nguyen K; McCormack JE; Driver DA; Townsend K; Ibañez CE; Sajjadi NC; Greengard JS; Moore MD; Respess J; Chang SM; Dubensky TW; Jolly DJ; Sauter SL
Mol Ther; 2000 Sep; 2(3):262-75. PubMed ID: 10985957
[TBL] [Abstract][Full Text] [Related]
19. A simple and reliable method for screening retroviral producer clones without selectable markers.
Onodera M; Yachie A; Nelson DM; Welchlin H; Morgan RA; Blaese RM
Hum Gene Ther; 1997 Jul; 8(10):1189-94. PubMed ID: 9215736
[TBL] [Abstract][Full Text] [Related]
20. A rapid procedure for screening fibroblast packaging cell lines for secretion of selectable retrovirus.
Elefanty AG; Cory S
Biotechniques; 1993 May; 14(5):770-4. PubMed ID: 8512701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
